Liew Woei Kang, Loh Wenyin, Chiang Wen Chin, Goh Anne, Chay Oh Moh, Iancovici Kidon Mona
Department of Paediatric Medicine, Allergy Service, KK Women's and Children's Hospital, Singapore 229899, Singapore.
Allergy and Clinical Immunology Unit, Sheba Medical Center, Tel Hashomer 5262100, Israel.
Asia Pac Allergy. 2015 Oct;5(4):222-9. doi: 10.5415/apallergy.2015.5.4.222. Epub 2015 Oct 28.
Children with a diagnosis of cross-reactive hypersensitivity to both paracetamol and nonsteroidal anti-inflammatory drugs are limited in their choice of antipyretics.
The aim of this pilot study is to evaluate the feasibility of using a Chinese proprietary medicine, Yin Qiao San (YQS), for fever relief.
A single centre, open label, prospective clinical trial exploring the tolerability and feasibility of using YQS for fever relief in children who are unable to use conventional antipyretic medications. Children between 1-18 years of age with hypersensitivity to multiple antipyretics were recruited. Eligible participants underwent an oral provocation test with YQS. Children who passed the oral provocation test were instructed to take a prescribed dose of YQS when the temperature was >38.0℃ and continued till the fever settled. Time taken for fever resolution and any adverse events were collected.
A total of 21 children, mean age 10.7 years, had a diagnosis of paracetamol and ibuprofen hypersensitivity. All except one patient successfully tolerated an oral challenge of YQS. Of the 88 doses of YQS taken for fever over 38.0℃, 16 (18%) had documented temperature reduction 2 hours after ingestion and 30 (34%) had documented temperature reduction 4 hours after ingestion. There were 2 reports of urticaria after YQS use which were attributed to flare of recurrent spontaneous urticaria during the illness. None of the patients developed symptoms of circulatory compromise or respiratory distress.
YQS is generally well tolerated in patients with paracetamol and ibuprofen hypersensitivity.
被诊断为对扑热息痛和非甾体抗炎药均有交叉反应性过敏的儿童，其退烧药的选择有限。
这项初步研究的目的是评估使用中成药银翘散（YQS）缓解发热的可行性。
一项单中心、开放标签、前瞻性临床试验，探讨在无法使用传统退烧药的儿童中使用YQS缓解发热的耐受性和可行性。招募了1至18岁对多种退烧药过敏的儿童。符合条件的参与者接受了YQS的口服激发试验。通过口服激发试验的儿童在体温>38.0℃时被指示服用规定剂量的YQS，并持续服用至退烧。收集退烧所需时间和任何不良事件。
共有21名儿童，平均年龄10.7岁，被诊断为对扑热息痛和布洛芬过敏。除一名患者外，所有患者均成功耐受了YQS的口服激发试验。在为体温超过38.0℃的发热服用的88剂YQS中，16剂（18%）在服药后2小时体温有记录下降，30剂（34%）在服药后4小时体温有记录下降。有2例在使用YQS后出现荨麻疹的报告，这归因于疾病期间复发性自发性荨麻疹的发作。没有患者出现循环功能障碍或呼吸窘迫的症状。
银翘散在对扑热息痛和布洛芬过敏的患者中通常耐受性良好。
